LCN2 / NGAL Protein & Antibody

Lipocalin 2 (Neutrophil Gelatinase-Associated Lipocalin)

LCN2 / NGAL Products

LCN2 / NGAL Protein, Recombinant

Molecule	Species	Description	Cat. No
LCN2/NGAL	Human	LCN2/NGAL Protein, Recombinant	10222-H08H
LCN2/NGAL	Mouse	LCN2/NGAL Protein, Recombinant	50060-M08H
LCN2/NGAL	Rat	LCN2/NGAL Protein, Recombinant	80058-R08B

  10222-H08H:  Recombinant human Lipocalin-2 can bind > 1.5 µM of Fe(DHBA)3. Measured by its ability to bind Iron(III) dihydroxybenzoic acid [Fe(DHBA)3]. The binding of Fe(DHBA)3 results in the quenching of Trp fluorescence in recombinant human Lipocalin-2.

  50060-M08H:  Recombinant human Lipocalin-2 can bind > 1.0 µM of Fe(DHBA)3. Measured by its ability to bind Iron(III) dihydroxybenzoic acid [Fe(DHBA)3]. The binding of Fe(DHBA)3 results in the quenching of Trp fluorescence in recombinant mouse Lipocalin-2.

  80058-R08B: It binds >1.0 µM of Fe(DHBA)3. Measured by its ability to bind Iron(III) dihydroxybenzoic acid [Fe(DHBA)3]. The binding of Fe(DHBA)3 results in the quenching of Trp fluorescence in Lipocalin2.

LCN2 / NGAL Antibody

Molecule	Application	Description	Cat. No
Human LCN2/NGAL	WB, ELISA	LCN2/NGAL Antibody, Rabbit PAb	10222-RP01
Human LCN2/NGAL	WB, ELISA	LCN2/NGAL Antibody, Rabbit Pab (Antigen Affinity Purified)	10222-RP02
Mouse LCN2/NGAL	WB, ELISA	Rabbit Polyclonal Antibody	50060-RP01
Mouse LCN2/NGAL	WB, ELISA	Rabbit Polyclonal Antibody (Antigen Affinity Purified)	50060-RP02

LCN2 / NGAL cDNA Clone

Molecule	Species	Description	Cat. No
LCN2/NGAL	Human	Homo sapiens LCN2/NGAL cDNA Clone(NM_005564.3)	HG10222-M
LCN2/NGAL	Mouse	Mus musculus LCN2/NGAL cDNA Clone	MG50060-M
LCN2/NGAL	Rat	Rat LCN2/NGAL cDNA Clone / ORF Clone	RG80058-M

LCN2 / NGAL Related Areas

Enzyme>>Protease & Regulator>>Metalloprotease & Regulator>>LCN2/NGAL

LCN2 / NGAL Alternative Names

LCN2, NGAL, MSFI, 24p3 [Homo sapiens]

Lcn2, 24p3, RP23-161B9.11, AW212229, Sip24 [Mus musculus]

LCN2 / NGAL Background

Lipocalin-2 (LCN2), also known as neutrophil gelatinase-associated lipocalin (NGAL), is a 25 kDa protein belonging to the lipocalin superfamily. It was initially found in activated neutrophils, however, many other cells, like kidney tubular cells, may produce NGAL in response to various insults. This protein is released from injured tubular cells after various damaging stimuli, is already known by nephrologists as one of the most promising biomarkers of incoming Acute Kidney Injury (AKI). Recent evidence also suggests its role as a biomarker in a variety of other renal and non-renal conditions. Moreover, recent studies seem to suggest a potential involvement of this factor also in the genesis and progression of chronic kidney diseases. NGAL is the first known mammalian protein which specifically binds organic molecules called siderophores, which are high-affinity iron chelators. NGAL, first known as an antibacterial factor of natural immunity, and an acute phase protein, is currently one of the most interesting and enigmatic proteins involved in the process of tumor development. acting as an intracellular iron carrier and protecting MMP9 from proteolytic degradation, NGAL has a clear pro-tumoral effect, as has already been observed in different tumors (e.g. breast, stomach, oesophagus, brain) in humans. In thyroid carcinomas, NGAL is strongly induced by NF-kB, an important factor involved both in tumor growth and in the link between chronic inflammation and neoplastic development. Thus, Lipocalin-2 (LCN2/NGAL) has been implicated in a variety of processes including cell differentiation, proliferation, survival and morphogenesis.

LCN2 / NGAL Related Studies

1. Schmidt-Ott KM, et al. (2006) Neutrophil gelatinase-associated lipocalin-mediated iron traffic in kidney epithelia. Curr Opin Nephrol Hypertens. 15(4): 442-9.
2. Bolignano D, et al. (2010) Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Lett. 288(1): 10-6.
3. Soni SS, et al. (2010) NGAL: a biomarker of acute kidney injury and other systemic conditions. Int Urol Nephrol. 42(1): 141-50.
4. Bolignano D, et al. (2010) From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology. Eur J Clin Invest. 40(3): 273-6.